TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill View
Don't Miss
Advertisement

Covid-19: Antibody cocktail treatment begins at Delhi’s Sir Ganga Ram Hospital

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

New Delhi, June 1

Advertisement

The Sir Ganga Ram Hospital on Tuesday started administering monoclonal antibody cocktail (MAC) to coronavirus patients, the medical facility said in a statement.

Advertisement

The hospital is administering a combination of casirivimab and imdevimab to consenting patients with mild and moderate Covid-19 symptoms at high risk of developing serious illness, it added.

The MRP of one MAC dose for a patient is Rs 59,750, the statement said.

According to the Drug Controller General of India (DCGI), selection of patients will entail that they have Covid positive test report, mild to moderate Covid disease, are in the age group of 12 and above and weighing at least 40 kg, and are at high risk of Covid-19.

Advertisement

Dr DS Rana, Chairman (BOM), Sir Ganga Ram Hospital said, “As per the claims of the company Roche/ Cipla, we hope MAC will be a major factor in the fight against Covid-19 to prevent disease from progressing to further severity.” PTI

Advertisement
Show comments
Advertisement